VAVictoria Abadi-Ron

Victoria Abadi-Ron

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Victoria Abadi-Ron has a total of 16 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Liver Stiffness, Patient-Reported Fatigue, and Pruritus in Primary Biliary Cholangitis and Primary Sclerosing Cholangitis: A Cross-Sectional Study

    by Victoria Abadi-Ron, Daniela Terrazas-Duque, Ana Marenco-Flores, Natalia Rojas-Amaris, Fernando Munguia, Romelia Barba Bernal, Daniela Goyes, John Esli Medina-Morales, Leandro Sierra, Behnam Saberi, et al.

    Background: Fatigue and pruritus are common and disabling in primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC), but their severity is not reliably explained by standard biochemical markers. Whether liver stiffness measured by transient elastography reflects these symptoms remains unclear. This study examined associations between liver stiffness and fatigue and pruritus in PBC and PSC, and between routine biochemical measures and symptom burden. Methods: This cross-sectional analysis included 107 patients (56 PBC, 51 PSC) from a prospective autoimmune liver disease registry. Fatigue was assessed with the CLDQ-29 fatigue domain and pruritus with the CLDQ-29 pruritus item or the itch visual analog scale. Multivariable linear and ordered logistic regression examined associations between liver stiffness and fatigue and pruritus, adjusted for disease type, age, and sex. Spearman correlations assessed associations between liver stiffness and clinical and laboratory variables, with Benjamini–Hochberg correction. Receiver operating characteristic analysis assessed discrimination. Results: Patients with PBC were older (59 vs. 51 years; p < 0.001) and more often female (96.4% vs. 56.9%; p < 0.001) than those with PSC. Liver stiffness (6.0 vs. 6.8 kPa; p = 0.101), fatigue scores, pruritus scores, and itch VAS were similar between groups. Liver stiffness was not associated with fatigue (β = 0.005; p = 0.835) or pruritus (OR = 0.97; p = 0.190) after adjustment; only age was associated with fatigue (β = 0.021; p = 0.020). Among laboratory measures, only ALP remained correlated with liver stiffness after correction (ρ = 0.309; adjusted p = 0.027). In PSC alone, higher liver stiffness was associated with worse pruritus (ρ = −0.37; p = 0.009), a finding not seen in PBC. Liver stiffness alone showed limited discrimination for fatigue (AUC 0.46) and pruritus (AUC 0.56); a model with disease type, age, and sex improved discrimination modestly for fatigue (AUC 0.60) but not for pruritus (AUC 0.57). Conclusions: Liver stiffness was not associated with fatigue or pruritus in the overall cohort of patients with PBC and PSC, and a possible association with pruritus in PSC needs confirmation. Patient-reported outcomes should be assessed alongside biochemical and elastographic measures, and how they relate to objective measures of disease remains an open question.

  • Open Access

    Current Treatment of Primary Biliary Cholangitis and Primary Sclerosing Cholangitis: A Comprehensive Review

    by Victoria E. Abadi-Ron, Ana Marenco-Flores, Natalia Rojas-Amaris, Fernando Munguía, Javier Olo-Ibarra, Behnam Saberi, Vilas R. Patwardhan, Alan Bonder

    Primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC) are chronic cholestatic liver diseases characterized by bile duct injury that may progress to fibrosis, cirrhosis, liver failure, and malignancy and ultimately require liver transplantation. Although these diseases share several clinical features, they differ substantially in pathogenesis, clinical course, and therapeutic approaches. Ursodeoxycholic acid remains the standard first-line therapy for PBC; patients with an inadequate biochemical response may be treated with second-line agents such as seladelpar, elafibranor, or fibrates. In contrast, no approved therapy has been shown to slow disease progression in PSC. Emerging therapies primarily target symptom and complication management, and overall management focuses on surveillance and timely referral for liver transplantation. This review summarizes current approaches to risk assessment, treatment, symptom management, monitoring, and transplantation decision-making in both conditions. Cite this article as: Abadi-Ron V, Marenco-Flores A, Rojas-Amaris N, et al. Current treatment of primary biliary cholangitis and primary sclerosing cholangitis: A comprehensive review. Turk J Gastroenterol. Published online June 19, 2026. doi: 10.5152/tjg.2026.26267

  • Open Access

    Longitudinal health-related quality of life and associated factors in autoimmune liver diseases

    by Dami Ko, Vilas Patwardhan, Natalia Rojas-Amaris, Victoria Abadi-Ron, Ana Marenco-Flores, Romelia Barba, Esli Medina-Morales, Leandro Sierra, Behnam Saberi, Alan Bonder